Abstract
Background: The Gitelman syndrome (GS) is an autosomal recessive disorder of renal tubular salt handling. Gitelman syndrome is characterized by hypokalemia, metabolic alkalosis, hypomagnesemia, hypocalciuria, and renin-angiotensin-aldosterone system (RAAS) activation, and is caused by variants in the SLC12A3 gene. Gitelman syndrome has a heterogeneous phenotype, which may or may not include a range of clinical signs, posing certain difficulties for clinical diagnosis.
Case presentation: A 49-year-old man was admitted to our hospital due to muscular weakness. The patient’s history revealed previous recurrent muscular weakness events associated with hypokalemia, featured by a minimum serum potassium value of 2.3 mmol/L. The reported male patient had persistent hypokalemia, hypocalciuria and normal blood pressure, without presenting obvious metabolic alkalosis, growth retardation, hypomagnesemia, hypochloremia or RAAS activation. We performed whole-exome sequencing and identified a novel compound heterozygous variant in the SLC12A3 gene, c.965-1_976delGCGGACATTTTTGinsACCGAAAATTTT in exon8 and c.1112T>C in exon9 in the proband.
Conclusion: This is a study to report a heterogeneous phenotype Gitelman syndrome with a novel pathogenic compound heterozygous variant in the SLC12A3 gene. This genetic study expands the variants spectrum, and improve the diagnostic accuracy of Gitelman syndrome. Meanwhile, further functional studies are required to investigate the pathophysiological mechanisms of Gitelman syndrome.
Introduction
Gitelman syndrome (GS) (OMIM 263800) is an inherited autosomal recessive salt-losing tubulopathy caused by biallelic inactivating variants in the SLC12A3 gene encoding a thiazide-sensitive sodium-chloride cotransporter (NCC), which is exclusively expressed in the apical membrane of cells lining the distal convoluted tubule (DCT) (Reyes and Medina, 2022). With a prevalence of approximately 1–10 per 40,000 cases, which is potentially higher in Asia. GS is an autosomal recessive disorder, but homozygous variants are found in only 18% of patients (Hsu et al., 2009; Blanchard et al., 2017; Wang et al., 2020). More than 45% of GS cases featured compound heterozygous variants, 30% had single heterozygous variants, and 7% exhibited three or more variants (Lee et al., 2016; Blanchard et al., 2017). The gender effect on phenotype in GS has been reported, with male patients carrying compound heterozygous variants leading to splicing defects and intrinsic functional alterations in NCC exhibiting severe phenotypes (Riveira-Munoz et al., 2007). Several variants in SLC12A3 and CLCNKB were identified in patients, and associated with clinical phenotypes in patients with GS and Gitelman-like syndrome (Lee et al., 2016; Kong et al., 2019). Here, we report a male patient with GS, characterized by a novel compound heterozygous variant of the SLC12A3 gene.
Materials and methods
Whole exome sequencing
Genomic DNA (gDNA) of patient was extracted from the peripheral blood using MagPure Buffy Coat DNA Midi KF Kit (Magen, China). Then, gDNA was broken into 100–500 bp fragments using enzyme kit (BGI, China), 280–320 bp fragments were collected by magnetic beads. Agilent 2100 bioanalyzer and BMG were used to estimate the enrichment degree, and qualified products were collected to make DNA nanoballs and quantified according to different library quantities. DNA nanoballs were sequenced with PE100 + 100 on MGISEQ-2000. The average sequencing depth of the target region is ≥ 200×, more than 96% of the locus have a coverage depth of >20×.
Case presentation
Clinical history and laboratory data
A 49-year-old male was presented to our hospital with the major complaints of fatigue, polydipsia, polyuria, and repeated muscle weakness, but without a history of salt craving, constipation, physical, and intellectual disability over a 30-year period. Due to the diagnosis of renal tubular acidosis 25 years earlier, the patient had token potassium sodium hydrogen citrate granules orally for a long time to maintain the blood potassium at 2.0–2.5 mmol/L. Two months earlier, the patient was admitted to the endocrinology department due to fatigue and developed hypokalemia. The patient was supplied with potassium chloride sustained release tablets. During the follow-up, serum potassium levels were maintained between 2.3 and 2.55 mmol/L. He was hospitalized in our department due to recurrent fatigue.
The patient had a height of 169 cm, weight of 69 kg, and a heart rate of 78 beats per minute with no growth retardation. His respiratory rate was 18 breaths per minute, temperature was 37.0°C, and 24-h urine volume was 1.9–2.4 L. We monitored the blood pressure of this patient twice a day, with the systolic blood pressure in the range of 95–123 mmHg, and the diastolic blood pressure in the range of 60–76 mmHg. The laboratory investigation revealed hypokalemia, hypocalciuria and normal blood pressure, without obvious metabolic alkalosis, hypomagnesemia, hypochloremia or RAAS activation (Table 1). The fractional excretion rate of potassium (FEK%) was significantly increased to 30.25% (normal range, 8%–12%) and spot potassium-creatinine ratio elevated to 7.33, suggesting that hypokalemia resulted from renal potassium loss (Table 1). Urinalysis showed microalbuminuria, normal urinary immunoglobulin IgG, elevated β2-microglobulinuria, and elevated urinary retinol binding protein, which indicated proximal tubular injury. Other possible causes of hypokalemia, such as thyrotoxic periodic paralysis, renal tubular acidosis, and hypercortisolism, were excluded. The enhanced computed tomography of adrenal gland showed possible right adrenal myelolipoma and left adrenal outer limb nodular protrusion, and hyperplasia was also considered (Supplementary Figure S1). Nevertheless, the renin-angiotensin-aldosterone system was normal, hence primary aldosteronism was excluded.
TABLE 1
| Variable | Test value | Reference range |
|---|---|---|
| Blood tests | ||
| Potassium (mmol/L) | 2.09 | 3.50–5.30 |
| Sodium (mmol/L) | 148 | 137–147 |
| Chloride (mmol/L) | 105 | 99–110 |
| Calcium (mmol/L) | 2.00 | 2.11–2.52 |
| Phosphate (mmol/L) | 0.46 | 0.85–1.51 |
| Magnesium (mmol/L) | 0.97 | 0.75–1.02 |
| Urea nitrogen (mmol/L) | 3.38 | 3.1–8.00 |
| Creatinine (μmol/L) | 102 | 57–97 |
| Fasting blood glucose (mmol/L) | 4.45 | 3.90–6.10 |
| Uric acid (μmol/L) | 302 | 208–428 |
| PTH(pg/mL) | 9.6 | 15–65 |
| ACTH (8AM) (pg/mL) | 30 | 0.00–46.00 |
| Renin–angiotensin–aldosterone system | ||
| Renin (upright) (μIU/mL) | 42.1 | 4.4–46.1 |
| Aldosterone (upright (pg/L) | 147 | 30–353.0 |
| ARR | 3.49 | |
| Renin (supine) (μIU/mL) | 17.3 | 2.8–39.9 |
| Aldosterone (supine) (pg/L) | 115 | 30–236.0 |
| Arterial blood gas analysis | ||
| PH | 7.408 | 7.35–7.45 |
| pCO2 | 39.7 | 35–45 |
| Bicarbonate (mmol/L) | 26.9 | 22–27 |
| Urine tests | ||
| PH | 8.0 | 4.5–8.0 |
| Urine protein (g/L) | ±(0.15) | - |
| MAU (g/mol.Cr) | 0.890 | 0.000–3.000 |
| Urinal β2 microglobulin (g/mol.Cr) | 2.478 | 0.000–0.045 |
| URBP(g/mol.Cr) | 1.305 | 0.000–0.105 |
| UACR (g/g) | 0.23 | 0–0.20 |
| Urinary aldosterone (μg/24 h) | 5.442 | 1.0–8.0 |
| urinary free cortisol (μg/24 h) | 260.4 | 20.9–292.3 |
| Calcium (mmol/24 h) | 1.9 | 2.5–7.5 |
| Potassium (mmol/24 h) | 80 | 25–100 |
| Magnesium (mmol/24 h) | 5.52 | 2.50–8.50 |
| Sodium (mmol/24 h) | 365 | 130–260 |
| Chloride (mmol/24 h) | 327 | 170–250 |
| Phosphate (μmol/24 h) | 11.8 | 12.9–42.0 |
| spot potassium-creatinine ratio | 7.33 | >2.0 mmol/mmol |
| spot calcium-creatinine ratio | 0.16 | <0.2 mmol/mmol |
| FEMg% | 4.64% | >4% |
| FECL% | 6.79% | >0.5% |
Biochemical characteristics of the proband.
The electrocardiogram (ECG) showed normal sinus rhythm, abnormality of T-waves but no prolongation of the QT interval. The urinary ultrasound showed kidneys with normal size and without obvious abnormality in the ureters (Supplementary Figure S2). The pure tone audiometry of the patient was normal. The ophthalmology examination indicated that sclerochoroidal calcifications could be excluded. A renal biopsy was performed, and the renal pathology revealed a mild injury of the renal tubular epithelium (Figure 1). The light microscope showed focal granular degeneration, cell swelling, brush edge falling off, and without tubular atrophy and tubulitis. Vacuolar degeneration of the renal tubular epithelial cells was observed, and no special lesions were found in the renal interstitium.
FIGURE 1
Diagnosis and treatment
The patient was diagnosed with GS based upon clinical features and biochemical parameters according to the criteria (Blanchard et al., 2017), whereas the confirmation of clinically suspected GS rested on genetic testing. The blood potassium was maintained at 3.3–3.5 mmol/L by clinical follow-up, with the addition of 3 g potassium chloride tablets in three divided doses and 40 mg spironolactone in two divided doses. Subsequently, the patient’s symptoms dramatically improved.
Whole exome sequence results
For a precise diagnosis, we performed whole-exome sequencing and identified a novel compound heterozygous variant in the SLC12A3 gene. One of the variants, SLC12A3 (NM_001126108.1, c.965-1_976delGCGGACATTTTTGinsACCGAAAATTTT) is caused by the deletion of 13 nucleotides GCGGACATTTTTG, and the insertion of 12 nucleotides ACCGAAAATTTT at nucleotide positions 965-976 of the coding sequence. Another variant SLC12A3 (NM_001126108.1, c.1112T>C, p.Ile371Thr) is caused by the substitution of nucleotide T with C. Sanger sequence were used to verify the mutations (Figures 2A, B).
FIGURE 2
Meanwhile, the sister of the proband had normal manifestations, no variants were found. Notably, a heterozygous variant (NM_001126108.1, c.965-1_976delGCGGACATTTTTGinsACCGAAAATTTT) was identified in the SLC12A3 gene in the proband’s daughter. The daughter is 24-year-old, appeared healthy, was found to have normal plasma potassium (4.2 mmol/L) and normal serum creatinine (67 μmol/L) levels. The serum potassium, sodium, chloride, calcium, and magnesium levels of the family members were unremarkable. The pedigree structure of the family was drawn according to the clinical manifestations and the sequencing results (Figure 2C).
Functional changes predictive of c.1112T>C variants
Variants were located in the intracellular and extracellular carboxyterminal domain of the NCC protein (Figure 3A). The variant (NM_001126108.1, c.965-1_976delGCGGACATTTTTGinsACCGAAAATTTT) in the SLC12A3 gene is a known GS associated variant (Shao et al., 2008; Wang et al., 2021). However, the variant SLC12A3 (NM_001126108.1, c.1112T>C, p.Ile371Thr) is not included in the databases (HGMD Professional and ClinVar). According to the American College of Medical Genetics and Genomics (ACMG) guidelines, the variation was judged to be of undetermined significance. The web-based software Variant Taster predicted that this variant was disease causing and capable of triggering amino acid sequence changes, frameshift, and splice site changes (Figure 3B). Two pathogenic in-trans variants in a single gene can produce the phenotype of this disease. Since the daughter of the proband carries only one of the two SLC12A3 variants, we can assume that these two variants are in-trans in the proband. In addition, we used CADD to predict the variant SLC12A3 (NM_001126108.1, c.1112T>C, p.Ile371Thr). The CADD-phred score is 26.8. We used mutation taster online website to predict and find that the variant is disease causing, and the prob is 0.999999999971332 (Figure 3B). Thus, the two variants may support the GS phenotype.
FIGURE 3
Three-dimensional structure prediction of SLC12A3 protein
Sequence alignment of SLC12A3 protein revealed that the isoleucine of p.371 was conserved among different species (Figure 3C). We used bioinformatics techniques to perform protein function prediction and secondary structure simulation (Supplementary Table S1). We used the SWISS-MODEL workspace (http://swissmodel.expasy.org) to characterize the effects of the novel variants, SLC12A3 (NM_001126108.1, c.965-1_976delGCGGACATTTTTGinsACCGAAAATTTT) and (NM_001126108.1, c.1112T>C, p.Ile371Thr) on the protein structure of NCC, which demonstrated that the alterations caused by the variants modified the protein structure, and might even affected the function in terms of NCC physiology. The variant SLC12A3 (NM_001126108.1, c.1112T>C, p.Ile371Thr) is only a point variant, with no significant change in the protein structure compared to wild type (Figures 3D, E). SLC12A3 (NM_001126108.1, c.965-1_976delGCGGACATTTTTGinsACCGAAAATTTT) cause protein structure changes into a smaller structure, may affect SLC12A3 protein function (Figure 3F).
Discussion
GS is characterized by hypokalemic metabolic alkalosis, hyperreninemia and hyperaldosteronemia. An adult patient subject to our case study was found with hypokalemia due to fatigue, and had been misdiagnosed as renal tubular acidosis for a long period. The long-term use of potassium sodium hydrogen citrate granules was insufficient for treatment. Based on the patient’s medical history and laboratory tests, the condition was conjectured to be GS with a heterogeneous phenotype.
Patients with GS with homozygous or compound heterozygous variants in CLCNKB and SLC12A3 were reported in many studies, and variants in CLCNKB in particular seem to be responsible for a mixed Bartter-Gitelman phenotype or at least are involved in a switch in the clinical phenotype (Zelikovic et al., 2003). Thus far, there has been no report of GS associated with compound heterozygous variants in SLC12A3. With a compound heterozygous variant in SLC12A3, our patient’s clinical manifestations were consistent with a heterogeneous phenotype GS in this study.
Features in an individual GS patient may vary. Patients are often asymptomatic or present with symptoms such as muscle weakness, fatigue, salt craving, thirst, nocturia, constipation, cramps, carpopedal spasms, or tetanic episodes triggered by hypomagnesemia (Blanchard et al., 2017). The presence of both hypocalciuria and hypomagnesemia is highly predictive of the clinical diagnosis of GS, although hypocalciuria is extremely variable and hypomagnesemia may be absent (Tseng et al., 2012). Some previous studies reported normomagnesemia in GS patients (Liu et al., 2016; Ma et al., 2016; Wang et al., 2017), which indicates that patients with normal magnesium exhibit milder clinical manifestations than hypomagnesemic patients (Jiang et al., 2014). Our patient’s blood magnesium levels were normal and without RAAS activation. Low to normal plasma aldosterone concentration in male patients may reflect the suppressive effect of aldosterone by more severe hypokalemia (Tseng et al., 2012). It has been confirmed in the phenotype analysis that male patients had more severe hypokalemia and associated neuromuscular symptoms than females (Riveira-Munoz et al., 2007; Tseng et al., 2012).
Research suggests that GS may be associated with proteinuria, and chronic kidney disease might develop in GS patients due to either chronic hypokalemia, which is associated with tubulointerstitial nephritis, tubule vacuolization and cystic changes, or volume depletion and increased reninangiotensin-aldosterone, which may contribute to renal damage and fibrosis (Blanchard et al., 2017). Our patient presented a low level of proteinuria, which included elevated β2-microglobulinuria and urinary retinol binding protein, indicating proximal tubular injury. Moreover, the renal biopsy showed tubulointerstitial injury, without obvious parabulbar organ hyperplasia.
In conclusion, this paper presented a case of novel compound heterozygous variants in the SLC12A3 gene (c.1112T>C and c.965-1_976delGCGGACATTTTTGinsACCGAAAATTTT) in a 49-year-old Chinese male with persistent hypokalemia, hypocalciuria, metabolic alkalosis and normal blood pressure, but without obvious metabolic alkalosis, hypomagnesemia, hypochloremia, or RAAS activation. The GS phenotype was complicated; accordingly, symptoms of GS are usually nonspecific and variable. This case expands the variants spectrum, and improve the diagnostic accuracy of GS. Thus far, the molecular basis of the phenotype variability in GS remains unknown, and it is not clear whether it has a critical role in managing patients and predicting their prognosis, hence further studies are needed to clarify the underlying mechanism.
Statements
Data availability statement
The original contributions presented in the study are included in the article’s Supplementary Material, further inquiries can be directed to the corresponding authors.
Ethics statement
All procedures performed in studies involving human participants were in accordance with the ethical standards of the Zhejiang University College of Medicine, the First Affiliated Hospital, and all pedigree members provided their written informed consent to participate. Written informed consent was obtained from the patient for publication of this study and any accompanying images.
Author contributions
WC and QZ participated in the experiments and wrote this article. HC was responsible for the sample and information collection. HL and JC guided the entire essay. All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
Funding
This work was supported by the Zhejiang Provincial Natural Science Foundation of China (LQ19H050004 to WC).
Acknowledgments
We are grateful to all the staff at the Kidney Disease Center of the First Affiliated Hospital of Zhejiang University for their sincere support.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Supplementary material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2023.1067242/full#supplementary-material
References
1
BlanchardA.BockenhauerD.BolignanoD.CalòL. A.CosynsE.DevuystO.et al (2017). Gitelman syndrome: Consensus and guidance from a kidney disease: Improving global outcomes (KDIGO) controversies conference. Kidney Int.91 (1), 24–33. 10.1016/j.kint.2016.09.046
2
HsuY. J.YangS. S.ChuN. F.SytwuH. K.ChengC. J.LinS. H. (2009). Heterozygous variants of the sodium chloride cotransporter in Chinese children: Prevalence and association with blood pressure. Nephrol. Dial. Transplant.24 (4), 1170–1175. official publication of the European Dialysis and Transplant Association - European Renal Association. 10.1093/ndt/gfn619
3
JiangL.ChenC.YuanT.QinY.HuM.LiX.et al (2014). Clinical severity of Gitelman syndrome determined by serum magnesium. Am. J. Nephrol.39 (4), 357–366. 10.1159/000360773
4
KongY.XuK.YuanK.ZhuJ.GuW.LiangL.et al (2019). Digenetic inheritance of SLC12A3 and CLCNKB genes in a Chinese girl with Gitelman syndrome. BMC Pediatr.19 (1), 114. 10.1186/s12887-019-1498-3
5
LaghmaniK.BeckB. B.YangS. S.SeaayfanE.WenzelA.ReuschB.et al (2016). Polyhydramnios, transient antenatal bartter's syndrome, and MAGED2 mutations. N. Engl. J. Med.374 (19), 1853–1863. 10.1056/NEJMoa1507629
6
LeeJ. W.LeeJ.HeoN. J.CheongH. I.HanJ. S. (2016). Mutations in SLC12A3 and CLCNKB and their correlation with clinical phenotype in patients with gitelman and gitelman-like syndrome. J. Korean Med. Sci.31 (1), 47–54. 10.3346/jkms.2016.31.1.47
7
LiuT.WangC.LuJ.ZhaoX.LangY.ShaoL. (2016). Genotype/phenotype analysis in 67 Chinese patients with gitelman's syndrome. Am. J. Nephrol.44 (2), 159–168. 10.1159/000448694
8
MaJ.RenH.LinL.ZhangC.WangZ.XieJ.et al (2016). Genetic features of Chinese patients with gitelman syndrome: Sixteen novel SLC12A3 mutations identified in a new cohort. Am. J. Nephrol.44 (2), 113–121. 10.1159/000447366
9
ReyesJ. V.MedinaP. (2022). Renal calcium and magnesium handling in Gitelman syndrome. Am. J. Transl. Res.14 (1), 1–19.
10
Riveira-MunozE.ChangQ.GodefroidN.HoenderopJ. G.BindelsR. J.DahanK.et al (2007). Transcriptional and functional analyses of SLC12A3 mutations: New clues for the pathogenesis of gitelman syndrome. J. Am. Soc. Nephrol. JASN18 (4), 1271–1283. 10.1681/ASN.2006101095
11
ShaoL.LiuL.MiaoZ.RenH.WangW.LangY.et al (2008). A novel SLC12A3 splicing mutation skipping of two exons and preliminary screening for alternative splice variants in human kidney. Am. J. Nephrol.28 (6), 900–907. 10.1159/000141932
12
TsengM. H.YangS. S.HsuY. J.FangY. W.WuC. J.TsaiJ. D.et al (2012). Genotype, phenotype, and follow-up in Taiwanese patients with salt-losing tubulopathy associated with SLC12A3 mutation. J. Clin. Endocrinol. metabolism97 (8), E1478–E1482. 10.1210/jc.2012-1707
13
WangF.ShiC.CuiY.LiC.TongA. (2017). Mutation profile and treatment of Gitelman syndrome in Chinese patients. Clin. Exp. Nephrol.21 (2), 293–299. 10.1007/s10157-016-1284-6
14
WangJ.XiangJ.ChenL.LuoH.XuX.LiN.et al (2021). Molecular diagnosis of non-syndromic hearing loss patients using a stepwise approach. Sci. Rep.11 (1), 4036. 10.1038/s41598-021-83493-6
15
WangX.DingY.LiuQ.YangG. (2020). A novel compound heterozygous mutation of SLC12A3 gene in a Chinese pedigree with Gitelman syndrome. Endocrine67 (3), 673–677. 10.1007/s12020-019-02152-z
16
ZelikovicI.SzargelR.HawashA.LabayV.HatibI.CohenN.et al (2003). A novel mutation in the chloride channel gene, CLCNKB, as a cause of Gitelman and Bartter syndromes. Kidney Int.63 (1), 24–32. 10.1046/j.1523-1755.2003.00730.x
Summary
Keywords
Gitelman syndrome, clinical characteristics, SLC12A3 gene, whole-exome sequencing, gene mutation
Citation
Chen W, Zhou Q, Chen H, Li H and Chen J (2023) Novel compound heterozygous variants of SLC12A3 gene in a Chinese patient with Gitelman syndrome: a case report. Front. Genet. 14:1067242. doi: 10.3389/fgene.2023.1067242
Received
11 October 2022
Accepted
04 May 2023
Published
12 June 2023
Volume
14 - 2023
Edited by
Ruth Roberts, ApconiX, United Kingdom
Reviewed by
Chih-Chien Sung, Tri-Service General Hospital, Taiwan
Lisa Gianesello, University of Padua, Italy
Updates
Copyright
© 2023 Chen, Zhou, Chen, Li and Chen.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Heng Li, hengli75@hotmail.com; Jianghua Chen, chenjianghua@zju.edu.cn
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.